A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Clinical trial NCT03075696 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03075696
- Sponsor
- Hoffmann-La Roche
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-02-21
- Primary completion
- 2029-03-30
- Enrollment
- 940
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.